Table 1.
Cohort studies that assessed TNF-I on ILD in rheumatoid arthritis
| Reference | Year | Study design | Research type | Region/population | Numbers | Data origin | Population | Experimental group | Control group | Objective | Conclusion |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Detorakis et al15 | 2017 | NA | Prospective | Greece | 168 | NA | RA | TNF-I | Non-biologic agents | Investigate the efficacy and safety of TNF-I compared to non-biologic DMARDs in RA | No new-onset ILD or exacerbation of preexisting-ILD, especially in patients with TNF-I supporting the efficacy and favorable safety profile of this treatment in RA patients |
| Druce et al14 | 2017 | NA | Retrospective | British | 352 | NA | RA-ILD | RTX | TNF-I | Compared mortality in patients with RA-ILD who revived RTX or TNF-I as their first biologic | Patients with RA-ILD who received rituximab had lower mortality rates compared to TNF-I |
| Nakashita et al10 | 2016 | Observational study | Retrospective | Japan | 62 | Single center | RA-ILD | ABA | TNF-I | Possible effect of abatacept on the progression of ILD in RA patients | Abatacept might have a lower risk of worsening pre-existing ILD than TNF-I |
| Koo et al13 | 2015 | NA | Retrospective | British | 24 | NA | RA-ILD | TNF (death) | TNF-I | Evaluate the impact on mortality of TNF-I treatment of RA-ILD | Lung complications can occur within months of initial anti-TNF treatment in older RA-ILD patients and TNF-I should be used with caution in these patients |
| Curtis et al12 | 2015 | Cohort | Retrospective | America | 13,795 | Data source | RA | TNF-I | ADA, RTX and CTR | Evaluate ILD incidence and the exacerbation among users of abatacept, rituximab, and tocilizumab compared with anti-TNF agents in adult RA patients | No significant differences in the risk of ILD and its related complications between RA patients receiving TNF-I and MOA agents |
| Nakashita et al10 | 2014 | Case-control | Retrospective | Japan | 163 | Single center | RA | TNF-I | Non-biologic agent | Assess the risks of TNF-I for patients with ILD | TNF-I have the potential risk of ILD events, particularly for patients with pre-existing ILD |
| Herrinton et al9 | 2013 | Cohort | Retrospective | America | 8,417 | Kaiser permanent Northern California | Autoimmune disease (RA) | ETA,INF and ADA | MTX | Evaluate the association of TNF-I with risks of ILD/PF among persons with the autoimmune disease compared with non-biologic therapy | Compared to non-biologic therapies TNF-I does not associate with a diagnosis of ILD |
Abbreviations: NA, unknown; RTX, rituximab; CTR, tocilizumab; ADA, adalimumab; ABA, abatacept TNF-I, tumor necrosis factor inhibitor; MTX, methotrexate; ILD, interstitial lung disease; PF, pulmonary failure; MOA, alternate mechanisms of action; RA, rheumatoid arthritis; DMARD, disease-modifying drugs; ETA, etanercept; INF, infliximab.